Halfway through earnings
season and analysts at BMO Capital Markets have noticed the following themes regarding MedTech companies:
- Q2 has no clear theme of upward revisions, like what the market saw in Q1
- Companies with large market
cap have beat revenue, and virtually all have beaten EPS estimates also
In a note to investors, BMO highlighted earnings this week in MedTech, noting that they are now focusing more on small-cap
names.
Monday, August 1
-
Haemonetics Corporation (NYSE: HAE):
Reported pre-market, Q1 EPS $0.25 vs $0.29 estimated, revenues of $209.96 million vs. $205.24 million estimated
-
Glaukos Corp (NYSE: GKOS): After hours
-
Orthofix International NV (NASDAQ: OFIX): After hours
Related Link: Biogen,
Ionis Reveal Nusinersen Meets Primary Endpoint At Interim Analysis Of Final Stage ENDEAR Trial
Tuesday
-
Mazor Robotics Ltd - ADR (NASDAQ: MZOR): Pre-market
-
Wright Medical Group Inc (NASDAQ: WMGI): After hours
-
Endologix, Inc. (NASDAQ: ELGX): After
hours
-
DexCom, Inc. (NASDAQ: DXCM): After
hours
-
Intersect ENT Inc (NASDAQ: XENT): After
hours
Wednesday
-
Insulet Corporation (NASDAQ: PODD):
After hours
-
STAAR Surgical Company (NASDAQ: STAA):
After hours
-
Cardiovascular Systems Inc (NASDAQ: CSII): After hours
-
K2M Group Holdings Inc (NASDAQ: KTWO):
After hours
Thursday
-
Becton Dickinson and Co (NYSE: BDX):
Pre-market
-
Hill-Rom Holdings, Inc. (NYSE: HRC):
Pre-market
-
Rewalk Robotics Ltd (NASDAQ: RWLK):
Pre-market
-
DENTSPLY SIRONA Inc (NASDAQ: XRAY):
Pre-market
-
AtriCure Inc. (NASDAQ: ATRC): After
hours
BMO expects fundamental to be in the spotlight as the remainder of earnings season unfolds.
Full ratings
data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win
a $20 Amazon gift card!
Latest Ratings for HAE
| Date |
Firm |
Action |
From |
To |
| May 2016 |
Goldman Sachs |
Upgrades |
Sell |
Neutral |
| Feb 2016 |
Jefferies |
Maintains |
|
Buy |
| Dec 2015 |
BTIG Research |
Initiates Coverage on |
|
Neutral |
View More Analyst Ratings for
HAE
View the Latest Analyst Ratings
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.